Skip to main content
Caplight Logo









NovaSterilis

NovaSterilis

Private
Lansing, New YorkHealthcare & Life Scienceshttps://novasterilis.com/

Last Round

Grant

Feb 1, 2024

Total Funding Raised

$7.39M

Company Overview

NovaSterilis is a biotechnology company that develops and manufactures supercritical carbon dioxide (scCO2) sterilization and decellularization technology platforms for the regenerative medicine, medical device, and pharmaceutical industries.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Medical Devices, Biotechnology, Clean Manufacturing

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Usage-Based SaaS

AI Layer

Non-AI

Keywords

supercritical CO2 sterilizationscCO2decellularizationsterility assurance levelSALbiotech equipmentterminal sterilizationgreen sterilizationmedical device sterilizationprocess validationregenerative medicinelow-temperature sterilizationclean manufacturingbiomaterial processingcontract sterilization

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

NovaSterilis Comparables

Compare NovaSterilis with similar companies based on industry and business-model similarity.

NovaSterilis comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Noxilizer
83%
Andersen Sterilizers, Inc.
74%
De Lama S.p.A.
69%

NovaSterilis Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 1, 2024
GrantSep 20, 2022
GrantJan 18, 2017
GrantFeb 1, 2015
GrantSep 1, 2012
Grant
Sep 15, 2011

NovaSterilis Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 7, 2025

    Presenting at the 34th Annual Conference of the European Society for Biomaterials.

  • Feb 1, 2024

    $1.75M grant from National Institute of Allergy and Infectious Diseases.

NovaSterilis Filings

Explore SEC and related filing metadata, where available.

NovaSterilis filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about NovaSterilis's valuation, stock price, and market status.

Is NovaSterilis a public or private company?

NovaSterilis is a private company.

What is the current stock price of NovaSterilis?

NovaSterilis is a private company with no public stock price. No recent secondary market data is available.

How much is NovaSterilis worth (valuation)?

Valuation information for NovaSterilis is not publicly available.

Can I buy NovaSterilis stock?

NovaSterilis shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was NovaSterilis's last funding round?

NovaSterilis's most recent funding round was Grant on February 23, 2024.

Who are the main investors in NovaSterilis?

Key investors in NovaSterilis include National Institute of Allergy and Infectious Diseases, NIH RADx, National Institute of General Medical Sciences.

Will NovaSterilis IPO soon?

No public IPO plans have been announced for NovaSterilis.

How can I track NovaSterilis secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NovaSterilis's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLansing, New York
Employee Range5
Year Founded2000
Last FundingFeb 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?